Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Acute lymphoblastic leukemia

Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia

Leukemia volume 34, pages 1154–1157 (2020)Cite this article

Subjects

In acute lymphoblastic leukemia (ALL), minimal residual disease (MRD) has been proven to have the strongest predictive value for relapse, independent of traditional prognostic factors.

Although MRD is conventionally measured in bone marrow aspirates (BM), modern sensitive molecular methods pose an attractive alternative: MRD monitoring in easily accessible body compartments, such as peripheral blood (PB).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Brisco MJ, Sykes PJ, Hughes E, Dolman G, Neoh SH, Peng LM, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol. 1997;99:314–9.

    Article  CAS  Google Scholar 

  2. van der Velden VHJ, Jacobs DCH, Wijkhuijs AJM, Comans-Bitter WM, Willemse MJ, Hählen K, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002;16:1432–6.

    Article  Google Scholar 

  3. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100:2399–402.

    Article  CAS  Google Scholar 

  4. Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, et al. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: a french multicenter study. Cytom Part B Clin Cytom. 2015;88:21–9.

    Article  Google Scholar 

  5. Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, et al. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018;71:653–8.

    Article  CAS  Google Scholar 

  6. Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, et al. Immunoglobulin and T Cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20:1307–13.

    Article  CAS  Google Scholar 

  7. Sala Torra O, Othus M, Williamson DW, Wood B, Kirsch I, Robins H, et al. Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2017;23:691–6.

    Article  CAS  Google Scholar 

  8. Volejnikova J, Mejstrikova E, Valova T, Reznickova L, Hodonska L, Mihal V, et al. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis. Haematologica. 2011;96:1815–21.

    Article  Google Scholar 

  9. Schumich A, Maurer‐Granofszky M, Attarbaschi A, Pötschger U, Buldini B, Gaipa G, et al. Flow‐cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B‐cell precursor acute lymphoblastic leukemia in trial AIEOP‐BFM‐ALL 2000. Pediatr Blood Cancer. 2019;66:e27590.

    Article  Google Scholar 

  10. van der Velden VHJ, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJM. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17:1013–34.

    Article  Google Scholar 

  11. van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11.

    Article  Google Scholar 

  12. Bain BJ, Bailey K. Pitfalls in obtaining and interpreting bone marrow aspirates: to err is human. J Clin Pathol. 2011;64:373–9.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Nicola Gökbuget, Monika Brüggemann

Authors and Affiliations

  1. Medical Department II, Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany

    Michaela Kotrova, Antonia Volland, Britta Kehden, Heiko Trautmann, Matthias Ritgen, Claudia D. Baldus & Monika Brüggemann

  2. Department of Internal Medicine I, University Hospital Freiburg, Freiburg, Germany

    Ralph Wäsch

  3. Department of Internal Medicine II, University Hospital Tübingen, Hematology, Tübingen, Germany

    Christoph Faul

  4. Department of Internal Medicine III, Hematology and Oncology, University Hospital Ulm, Ulm, Germany

    Andreas Viardot

  5. Department of Hematology, Charité Campus Benjamin Franklin, Berlin, Germany

    Stefan Schwartz

  6. Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany

    Nicola Gökbuget

Authors
  1. Michaela Kotrova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonia Volland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Britta Kehden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heiko Trautmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthias Ritgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ralph Wäsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christoph Faul
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Viardot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stefan Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Claudia D. Baldus
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nicola Gökbuget
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Monika Brüggemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Brüggemann.

Ethics declarations

Conflict of interest

NG: Consultancy for Amgen, Pfizer, Novartis, Celgene, Kite/Gilead; Travel support and Research Funding for Amgen, Pfizer, Novartis. SS: Speaker honoraria, travel grant from: Basilea Pharmaceutica, Gilead, MSD Sharp & Dohme, Pfizer; Advisory Board of: Basilea Pharmaceutica, BTG International Inc., Gilead, MSD Sharp & Dohme; Travel grant: BTG International Inc.; Reimbursement for treatment and monitoring of study participants: GlaxoSmithKline. MB: contract research for Affimed, Amgen, Regeneron, advisory board of Amgen, Incyte; speaker bureau of Janssen, Pfizer, Roche. AVi: Advisory board: Pfizer, Roche, Amgen, Kite/Gilead; Honoraria: Pfizer, Roche; Travel grants: Kite/ Gilead, Roche, Abbvie, Janssen. The remaining authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kotrova, M., Volland, A., Kehden, B. et al. Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia 34, 1154–1157 (2020). https://doi.org/10.1038/s41375-019-0599-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0599-1

This article is cited by

Search

Advanced search

Quick links